Aastrom Biosciences to Host Third Quarter 2013 Investor Call on November 12, 2013
07 nov. 2013 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Announces Results of Two Studies of Ixmyelocel-T Published in Stem Cell Research & Therapy
01 nov. 2013 12h10 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Nov. 1, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences Regains Compliance With NASDAQ Minimum Bid Requirement
31 oct. 2013 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences One-for-Twenty Reverse Stock Split Now Effective
16 oct. 2013 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Oct. 16, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences Announces One-for-Twenty Reverse Stock Split
10 oct. 2013 16h15 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences to Present at the 2013 Stem Cell Meeting on the Mesa Conference
10 oct. 2013 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences to Present at the Aegis Capital 2013 Healthcare Conference
19 sept. 2013 09h00 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Clinical Trial Application for Phase 2b ixCELL-DCM Study of ixmyelocel-T Approved in Canada
16 sept. 2013 09h20 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Sept. 16, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Heidi Hagen Joins Aastrom Board of Directors
26 août 2013 16h05 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 26, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences, Inc. Announces Closing of Public Offering of Common Stock and Warrants
16 août 2013 11h07 HE
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 16, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...